Diabetes drug safety tracked in 1,000+ patients
NCT ID NCT07210307
Summary
This study monitored 1,001 adults with type 2 diabetes in Vietnam who were newly prescribed Forxiga (dapagliflozin). Researchers followed patients for 24 weeks to track any side effects that occurred during routine medical care. The goal was to understand the real-world safety profile of this already-approved diabetes medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY OUTCOMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HCMC Heart Institute
Ho Chi Minh City, Vietnam
Conditions
Explore the condition pages connected to this study.